Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Requirement for the E1 Helicase C-Terminal Domain in Papillomavirus DNA Replication In Vivo.

Bergvall M, Gagnon D, Titolo S, Lehoux M, D'Abramo CM, Melendy T, Archambault J.

J Virol. 2016 Jan 6;90(6):3198-211. doi: 10.1128/JVI.03127-15.

2.

Enantiomeric atropisomers inhibit HCV polymerase and/or HIV matrix: characterizing hindered bond rotations and target selectivity.

LaPlante SR, Forgione P, Boucher C, Coulombe R, Gillard J, Hucke O, Jakalian A, Joly MA, Kukolj G, Lemke C, McCollum R, Titolo S, Beaulieu PL, Stammers T.

J Med Chem. 2014 Mar 13;57(5):1944-51. doi: 10.1021/jm401202a. Epub 2013 Sep 30.

PMID:
24024973
3.

Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes.

Lamorte L, Titolo S, Lemke CT, Goudreau N, Mercier JF, Wardrop E, Shah VB, von Schwedler UK, Langelier C, Banik SS, Aiken C, Sundquist WI, Mason SW.

Antimicrob Agents Chemother. 2013 Oct;57(10):4622-31. doi: 10.1128/AAC.00985-13. Epub 2013 Jul 1.

4.

A novel inhibitor-binding site on the HIV-1 capsid N-terminal domain leads to improved crystallization via compound-mediated dimerization.

Lemke CT, Titolo S, Goudreau N, Faucher AM, Mason SW, Bonneau P.

Acta Crystallogr D Biol Crystallogr. 2013 Jun;69(Pt 6):1115-23. doi: 10.1107/S0907444913006409. Epub 2013 May 15.

PMID:
23695256
5.

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moiety.

Fader LD, Landry S, Goulet S, Morin S, Kawai SH, Bousquet Y, Dion I, Hucke O, Goudreau N, Lemke CT, Rancourt J, Bonneau P, Titolo S, Amad M, Garneau M, Duan J, Mason S, Simoneau B.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3401-5. doi: 10.1016/j.bmcl.2013.03.074. Epub 2013 Apr 3.

PMID:
23601710
6.

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: addressing configurational instability through scaffold modification.

Fader LD, Landry S, Morin S, Kawai SH, Bousquet Y, Hucke O, Goudreau N, Lemke CT, Bonneau P, Titolo S, Mason S, Simoneau B.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3396-400. doi: 10.1016/j.bmcl.2013.03.073. Epub 2013 Mar 28.

PMID:
23583513
7.

Novel inhibitor binding site discovery on HIV-1 capsid N-terminal domain by NMR and X-ray crystallography.

Goudreau N, Lemke CT, Faucher AM, Grand-Maître C, Goulet S, Lacoste JE, Rancourt J, Malenfant E, Mercier JF, Titolo S, Mason SW.

ACS Chem Biol. 2013 May 17;8(5):1074-82. doi: 10.1021/cb400075f. Epub 2013 Mar 25.

PMID:
23496828
8.

Discovery and structural characterization of a new inhibitor series of HIV-1 nucleocapsid function: NMR solution structure determination of a ternary complex involving a 2:1 inhibitor/NC stoichiometry.

Goudreau N, Hucke O, Faucher AM, Grand-Maître C, Lepage O, Bonneau PR, Mason SW, Titolo S.

J Mol Biol. 2013 Jun 12;425(11):1982-1998. doi: 10.1016/j.jmb.2013.02.022. Epub 2013 Feb 26.

PMID:
23485336
9.

Monitoring binding of HIV-1 capsid assembly inhibitors using (19)F ligand-and (15)N protein-based NMR and X-ray crystallography: early hit validation of a benzodiazepine series.

Goudreau N, Coulombe R, Faucher AM, Grand-Maître C, Lacoste JE, Lemke CT, Malenfant E, Bousquet Y, Fader L, Simoneau B, Mercier JF, Titolo S, Mason SW.

ChemMedChem. 2013 Mar;8(3):405-14. doi: 10.1002/cmdc.201200580. Epub 2013 Feb 10.

PMID:
23401268
10.

Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold.

Tremblay M, Bonneau P, Bousquet Y, DeRoy P, Duan J, Duplessis M, Gagnon A, Garneau M, Goudreau N, Guse I, Hucke O, Kawai SH, Lemke CT, Mason SW, Simoneau B, Surprenant S, Titolo S, Yoakim C.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7512-7. doi: 10.1016/j.bmcl.2012.10.034. Epub 2012 Oct 16.

PMID:
23122820
11.

Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein.

Lemke CT, Titolo S, von Schwedler U, Goudreau N, Mercier JF, Wardrop E, Faucher AM, Coulombe R, Banik SS, Fader L, Gagnon A, Kawai SH, Rancourt J, Tremblay M, Yoakim C, Simoneau B, Archambault J, Sundquist WI, Mason SW.

J Virol. 2012 Jun;86(12):6643-55. doi: 10.1128/JVI.00493-12. Epub 2012 Apr 11.

12.

Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly.

Fader LD, Bethell R, Bonneau P, Bös M, Bousquet Y, Cordingley MG, Coulombe R, Deroy P, Faucher AM, Gagnon A, Goudreau N, Grand-Maître C, Guse I, Hucke O, Kawai SH, Lacoste JE, Landry S, Lemke CT, Malenfant E, Mason S, Morin S, O'Meara J, Simoneau B, Titolo S, Yoakim C.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):398-404. doi: 10.1016/j.bmcl.2010.10.131. Epub 2010 Oct 31.

PMID:
21087861
13.

Characterization of papillomavirus E1 helicase mutants defective for interaction with the SUMO-conjugating enzyme Ubc9.

Fradet-Turcotte A, Brault K, Titolo S, Howley PM, Archambault J.

Virology. 2009 Dec 20;395(2):190-201. doi: 10.1016/j.virol.2009.09.020.

14.

Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor.

Wang Y, Coulombe R, Cameron DR, Thauvette L, Massariol MJ, Amon LM, Fink D, Titolo S, Welchner E, Yoakim C, Archambault J, White PW.

J Biol Chem. 2004 Feb 20;279(8):6976-85. Epub 2003 Nov 22.

15.

Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1-E2 protein interaction.

White PW, Titolo S, Brault K, Thauvette L, Pelletier A, Welchner E, Bourgon L, Doyon L, Ogilvie WW, Yoakim C, Cordingley MG, Archambault J.

J Biol Chem. 2003 Jul 18;278(29):26765-72. Epub 2003 Apr 30.

16.
18.

Characterization of recombinant HPV6 and 11 E1 helicases: effect of ATP on the interaction of E1 with E2 and mapping of a minimal helicase domain.

White PW, Pelletier A, Brault K, Titolo S, Welchner E, Thauvette L, Fazekas M, Cordingley MG, Archambault J.

J Biol Chem. 2001 Jun 22;276(25):22426-38. Epub 2001 Apr 13.

19.

Identification of domains of the human papillomavirus type 11 E1 helicase involved in oligomerization and binding to the viral origin.

Titolo S, Pelletier A, Pulichino AM, Brault K, Wardrop E, White PW, Cordingley MG, Archambault J.

J Virol. 2000 Aug;74(16):7349-61.

20.

Identification of domains of the HPV11 E1 protein required for DNA replication in vitro.

Amin AA, Titolo S, Pelletier A, Fink D, Cordingley MG, Archambault J.

Virology. 2000 Jun 20;272(1):137-50.

21.

Role of the ATP-binding domain of the human papillomavirus type 11 E1 helicase in E2-dependent binding to the origin.

Titolo S, Pelletier A, Sauvé F, Brault K, Wardrop E, White PW, Amin A, Cordingley MG, Archambault J.

J Virol. 1999 Jul;73(7):5282-93.

Supplemental Content

Loading ...
Support Center